There have been documented significant cases of peliosis hepatis, often linked to liver failure and intra-abdominal hemorrhage; liver tumors, occasionally deadly; and blood lipid variations connected with increased danger of atherosclerosis led FDA to eliminate acceptance in June 2023. Additional warnings involve the pitfalls related to cholestatic… Read More